EIF4A3 inhibition not only reduces tumor proliferation, migration, and angiogenesis, but it also shortens the half-life of VEGFA, suggesting that LINC00667-VEGFA-EIF4A3 is an oncogenic pathway in NSCLC. Here, EIF4A3 is linked to neoplasm.